New drug to stop 'Ozempic butt' muscle loss side effect of obesity jabs
A third of the weight loss from obesity jabs can come from muscle, say experts.
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"The findings were promising but should be viewed as 'encouraging early evidence' rather than definitive proof of clinical benefit."
— Dr Marie Spreckley , Academic
"The treatment might not be suitable for everyone on GLP-1 drugs, but might help some who are losing muscle mass particularly fast."
— Dr Brendan Gabriel , Academic
"The findings were promising but should be viewed as 'encouraging early evidence' rather than definitive proof of clinical benefit."
— Dr Marie Spreckley , Academic
Key People
Tags
All Coverage
A third of the weight loss from obesity jabs can come from muscle, say experts.
Researchers are developing a new medication to combat muscle loss associated with popular weight loss injections, as up to one-third of weight reduction from obesity jabs comes from muscle tissue.
A new muscle growth drug called apitegromab significantly reduced lean tissue loss for patients using GLP-1 slimming jabs during a 24-week clinical trial, allowing patients to retain 55% more muscle mass compared to those receiving a placebo.
A new drug called apitegromab could help people on obesity jabs avoid unwanted muscle decline that’s been linked to flat bums or “Ozempic butt”, according to research in the Nature Medicine journal.
Researchers are developing a new medication to combat muscle loss associated with popular weight loss injections. Experts say up to one-third of weight reduction from obesity jabs comes from muscle tissue.
A new muscle growth drug called apitegromab significantly reduced lean tissue loss for patients using GLP-1 slimming jabs during a 24-week clinical trial published in Nature Medicine on June 8, 2026.
A new drug called apitegromab could help people on obesity jabs avoid unwanted muscle decline that's been linked to flat bums or 'Ozempic butt', according to research in Nature Medicine journal.
A new drug called apitegromab could help people on obesity jabs avoid unwanted muscle decline that's been linked to flat bums or 'Ozempic butt', according to research in Nature Medicine journal.
Similar Stories
Related coverage based on topic and tags
New weight-loss pill approved for use in UK
Foundayo is made by Eli Lilly, the drug firm behind the Mounjaro jab.
August 10, 2026 at 03:25 PMLilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - reuters.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide reuters.com
August 12, 2026 at 10:27 AMWeekly type 2 diabetes jab could replace daily injections
Hundreds of thousands of people with type 2 diabetes could get access to a new weekly insulin jab to replace daily injections.
August 20, 2026 at 12:39 AMNovo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Novo CEO says obesity market won't be winner-take-all battle with Lilly reuters.com
August 13, 2026 at 10:02 AMNovo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026 at 03:26 PMEyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026 at 03:45 PM